Market
What will be lenacapavir's impact on global HIV infection rates by 2025?
2
Resolution / Starting Odds
Reduction by less than 5% • 25%
Reduction by 5% to 10% • 25%
Reduction by 10% to 15% • 25%
Reduction by more than 15% • 25%
Reports from UNAIDS and global health organizations
Story
Gilead's Lenacapavir: Science's 2024 Breakthrough for HIV Prevention
Dec 13, 2024, 07:30 AM
Gilead Sciences' lenacapavir, a long-acting injectable drug for HIV prevention, has been named the 2024 Breakthrough of the Year by the journal Science. Lenacapavir, which requires only a single shot every six months, demonstrated near-perfect efficacy in clinical trials, preventing HIV infections in 99.9% of participants. The drug targets the HIV capsid, disrupting key stages of viral replication, offering a novel mechanism of action. This development is seen as a significant step towards reducing the global HIV/AIDS epidemic. However, the high cost of lenacapavir poses a potential barrier to its widespread use, particularly in low-income regions. Gilead has made agreements to produce generic versions for 120 of the world's poorest countries, but middle-income nations like Brazil are excluded, sparking concerns about access and affordability.
View original story
Similar markets
20% to 30% • 25%
Less than 10% • 25%
More than 30% • 25%
10% to 20% • 25%
Less than 10% • 25%
More than 30% • 25%
20% to 30% • 25%
10% to 20% • 25%
100% or more • 25%
Less than 50% • 25%
50% to 75% • 25%
76% to 99% • 25%
